AbbVie joins cancer-focused ORIEN Avatar Research Programme

AbbVie has become the newest member of the Oncology Research Information Exchange Network (ORIEN) Avatar Research Programme, becoming the fourth pharmaceutical company to sign up.

Launched in April 2016 and managed by M2Gen, the programme is designed to foster collaboration among key stakeholders in cancer research, with the overall goal of aiding the discovery and development of novel therapies through clinical trials.

It represents an alliance between the 15 leading US cancer hospitals that comprise ORIEN and leading pharmaceutical companies, with cancer researchers contributing samples and disease information from consenting patients to help identify eligible participants for clinical trials.

The pharmaceutical partners contribute financial support, with all parties receiving access to anonymised genetic and disease information that can be used to inform the discovery and clinical development of new cancer drugs.

Steve Davidsen, vice-president for oncology discovery at AbbVie, said: "Through the collaborative efforts of the ORIEN Avatar participants, we can magnify the collective data on specific tumour types and biomarkers to catalyse future discoveries for patients in need."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.